The SURPASS-CVOT trial offers critical data comparing the cardiovascular safety of tirzepatide against dulaglutide in patients managing type 2 diabetes (T2D). The findings confirm that **Tirzepatide CV outcomes** were not worse than those of dulaglutide. Tirzepatide acts as a dual agonist targeting both GLP-1 and GIP receptors, consequently offering favorable effects on both glycemic control and body weight. Therefore, this study was essential to address the uncertainty regarding its cardiovascular impact, especially when compared to a proven agent like dulaglutide.
Trial Design and Patient Population
Investigators conducted a double-blind, active-comparator-controlled, noninferiority trial. The participants all had T2D and pre-existing atherosclerotic cardiovascular disease (ASCVD). Researchers randomly assigned over 13,000 patients to receive either a weekly subcutaneous injection of tirzepatide (up to 15 mg) or dulaglutide (1.5 mg). Dulaglutide is an established agent known to reduce the incidence of cardiovascular events. The average age of the patients was 64.1 years. Furthermore, the mean body-mass index was high, averaging 32.6. Patients had long-standing diabetes, with a mean duration of 14.7 years. Because of these factors, the study population represented a high-risk group.
Key Findings on Tirzepatide CV Outcomes
The primary endpoint was a major adverse cardiovascular event (MACE) composite: death from CV causes, myocardial infarction, or stroke. Consequently, the trial aimed to establish noninferiority for tirzepatide compared to dulaglutide. An event occurred in 12.2% of the tirzepatide group and 13.1% of the dulaglutide group. The hazard ratio was 0.92 (95.3% confidence interval, 0.83 to 1.01). Importantly, the trial met the noninferiority margin (P=0.003 for noninferiority). This noninferiority finding is crucial for the regulatory profile of tirzepatide. However, the study did not meet the prespecified threshold for superiority (P=0.09).
Safety and Adverse Events
The incidence of overall adverse events was similar between the two treatment arms. Nevertheless, the tirzepatide group did report more gastrointestinal adverse events. Specifically, side effects like nausea, vomiting, and diarrhea were more frequently observed with tirzepatide. Physicians should counsel patients about these potential side effects when initiating tirzepatide therapy.
Frequently Asked Questions
Q1: What was the primary conclusion of the SURPASS-CVOT trial?
The primary conclusion was that tirzepatide was noninferior to dulaglutide with respect to the composite cardiovascular outcome of CV death, myocardial infarction, or stroke.
Q2: Why is the noninferiority finding significant for tirzepatide?
The noninferiority finding is significant because dulaglutide is a proven CV risk-reducing agent. This result allows tirzepatide, which also offers superior glycemic and weight benefits, to be used broadly in high-risk T2D patients with ASCVD.
Q3: What were the main adverse events noted in the tirzepatide group?
Although the overall adverse event rates were similar, the tirzepatide group experienced a higher incidence of gastrointestinal adverse events, including nausea, vomiting, and diarrhea.
References
- Nicholls SJ et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025 Dec 18. doi: 10.1056/NEJMoa2505928. PMID: 41406444.
- Clinical data on Tirzepatide. Accessed December 2025.
- SURPASS-CVOT Trial Summary. Accessed December 2025.
- Regulatory News on Incretin Agonists. Accessed December 2025.